Latest Articles
Labor’s Half A Billion Dollar Investment in Women’s Health: What’s In It For You? - Inkl
Labor’s Half A Billion Dollar Investment in Women’s Health: What’s In It For You? Inkl
Published: Feb. 10, 2025, 4:16 a.m.
Labor’s Half A Billion Dollar Investment in Women’s Health: What’s In It For You? - Pedestrian.TV
Labor’s Half A Billion Dollar Investment in Women’s Health: What’s In It For You? Pedestrian.TV
Published: Feb. 10, 2025, 4:14 a.m.
Labor to have ‘big focus on health’ in lead up to next election - MSN
Labor to have ‘big focus on health’ in lead up to next election MSN
Published: Feb. 8, 2025, 11:17 p.m.
Federal Labor promises half a billion dollars for women's health, including better access to long-term contraceptives - ABC News
Federal Labor promises half a billion dollars for women's health, including better access to long-term contraceptives ABC News
Published: Feb. 8, 2025, 11:31 a.m.
Bayer aims to expand presence in India with new therapies and strategic collaborations - MSN
Bayer aims to expand presence in India with new therapies and strategic collaborations MSN
Published: Jan. 8, 2025, 11:49 a.m.
Prolonged third stage of labor linked to increased postpartum hemorrhage risk - Contemporary Obgyn
Prolonged third stage of labor linked to increased postpartum hemorrhage risk Contemporary Obgyn
Published: Jan. 6, 2025, 5:24 p.m.
Proteomics International Laboratories Ltd (ASX:PIQ) Breakthrough Results for Endometriosis Diagnostic Blood Test - ABN Newswire
Proteomics International Laboratories Ltd (ASX:PIQ) Breakthrough Results for Endometriosis Diagnostic Blood Test ABN Newswire
Published: Dec. 29, 2024, 10:22 p.m.
Addressing women’s health: Collaborative effort to combat endometriosis - VietNamNet
Addressing women’s health: Collaborative effort to combat endometriosis VietNamNet
Published: Nov. 22, 2024, 9:30 a.m.
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® - The Manila Times
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® The Manila Times
Published: Nov. 7, 2024, 1:16 p.m.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous …
Published: May 20, 2024, 7 a.m.
Link copied to clipboard!